What is the interaction between Vitamin B12 and Tyrosine Kinase Inhibitors (TKI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Vitamin B12 supplementation is crucial for patients taking tyrosine kinase inhibitors (TKIs) to prevent deficiency and minimize adverse effects. The rationale for this recommendation is based on the potential of TKIs to affect gastric acid secretion and intrinsic factor production, potentially reducing B12 absorption 1. Additionally, some TKIs may increase metabolic demands, potentially depleting B12 stores more rapidly. Maintaining optimal B12 levels helps support normal DNA synthesis, neurological function, and red blood cell formation, which may improve tolerance to TKI therapy.

Key Considerations

  • Patients on TKIs like imatinib, erlotinib, or sunitinib should maintain adequate B12 levels to prevent exacerbation of fatigue and neuropathy, common side effects of these medications.
  • A typical supplementation regimen includes oral cyanocobalamin 1000-2000 mcg daily, though some patients may require B12 injections (1000 mcg monthly) if they have absorption issues.
  • It's advisable to check B12 levels before starting TKI therapy and monitor periodically, especially in patients with risk factors for deficiency such as older age, vegetarian diet, or gastrointestinal disorders.

Recent Evidence

A recent study published in 2021 2 investigated the use of high-dose tyrosine kinase inhibitors to improve clinical benefit, but did not specifically address the issue of B12 supplementation. However, the study highlights the importance of optimizing TKI dosing regimens to minimize adverse effects and improve patient outcomes.

Clinical Implications

In clinical practice, it is essential to prioritize the prevention of B12 deficiency in patients taking TKIs to minimize the risk of adverse effects and improve quality of life. By maintaining optimal B12 levels, healthcare providers can help support normal DNA synthesis, neurological function, and red blood cell formation, ultimately improving patient outcomes. As noted in a study published in 2018 3, drug-drug interactions involving TKIs are common, and B12 supplementation may be necessary to mitigate these interactions.

References

Research

Drug-drug interactions in patients receiving tyrosine kinase inhibitors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.